Company news

Sana Biotechnology, Inc. (NASDAQ:SANA) news

Sana Biotechnology, Inc. news releases on 6ix. Latest, Feb 13, 2024: Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell…

Sana Biotechnology, Inc. (NASDAQ:SANA) news

Press releases — page 2

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sana Biotechnology Announces Pricing of Upsized Public Offering

Sana Biotechnology Announces Proposed Public Offering of Common Stock

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology to Present at November and December 2023 Investor Conferences

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

Sana Biotechnology to Present at September 2023 Investor Conferences

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

Sana Biotechnology to Present at June 2023 Investor Conferences

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

Sana Biotechnology to Present at May 2023 Investor Conferences

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

Sana Biotechnology to Host Research & Development Day

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting

Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates

Sana Biotechnology to Present at September 2022 Investor Conferences

Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory

Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute

Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference

Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates